GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-07-18| Trials & Approvals

Aftermath of Biogen’s Alzheimer’s Drug Approval Continues as Some Hospitals, Insurers Refuse Administration

by Daniel Ojeda
Share To

July 17th, 2021 – Biogen and Eisai Co.’s Alzheimer’s drug, Aduhelm (aducanumab), suffered two more blowbacks this week. First, a panel of experts convened by the Institute of Clinical and Economic Review (ICER) voted unanimously that there is no evidence to say the drug offers significant health benefits. Then, two major health systems announced they would not carry Aduhelm. At the end of the week, the news pushed Biogen’s stock down more than 8%.

Aduhelm became the first drug approved to treat Alzheimer’s disease (AD) in nearly 20 years. However, the approval has faced a lot of criticism for two main reasons: 

  • Experts are not convinced it offers significant health benefits. An FDA advisory panel voted 7 against, 4 uncertain, and 0 in favor that the Phase 3 clinical trial demonstrated its efficacy.
  • Its exorbitant price tag of $56,000 could make it inaccessible for uninsured people and even those insured if insurers do not cover the cost.

Following the pushback from various quarters, on July 8th, the FDA updated Aduhelm’s label, narrowing its administration to only patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia.

Additionally, Dr. Janet Woodcock, the Acting Commissioner of the FDA, asked the Inspector General last week to investigate interactions between Biogen and FDA review staff to ensure they were consistent with FDA’s policies and procedures.

 

Roadblocks with Experts and Insurers

With the possible lack of health benefits and the high price, the Cleveland Clinic and New York’s Mount Sinai Health System announced they would not carry Aduhelm. The news sent Biogen’s stock price crashing almost 7% on Thursday.

Later that day, a panel of experts voted 15-0 during a meeting organized by the ICER that there is no evidence Aduhelm provides net health benefits. Additionally, the ICER said the drug is cost-effective at no more than $8,400. That is 15% of the current price listed by Biogen.

Another roadblock on Aduhelm’s way is coverage by insurers. Blue Cross Blue Shield health insurance plans from Michigan, North Carolina, and Pennsylvania already announced they will not cover the drug due to insufficient evidence regarding benefits to the patients. 

Similarly, UnitedHealth, and Humana, the first- and second-largest providers of Medicare Advantage, respectively, announced they were awaiting input from Centers for Medicare and Medicaid Services (CMS) before finalizing coverage.

For their part, CMS began a 9-month long national review process on Monday to determine the nationwide conditions for coverage. Until then, approval determinations will be made by 12 regional contractors at the local level.

Andrew Witty, CEO of UnitedHealth, said to Reuters, “This has some way to go before we get to real clarity. So I wouldn’t guide you to expect a very rapid decision-making on this piece,” 

Biogen’s stocks were down more than 8% by the end of the week, and Eisai Co.’s stock decreased by almost 13%. Friday’s closing price of Biogen’s stock was $324.64, which is 25% lower than the peak price it reached after Aduhelm’s FDA approval.

Related Article: FDA Grants Breakthrough Status to Two Experimental Alzheimer’s Drugs While Pushback Over Aduhelm’s Approval Still Rages On

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
Easing the Mental Health Burden: How MDMA, Psilocybin, and Other Psychedelics May Open Doors for Treating PTSD, Addiction, and Autism
2025-01-28
Drug Promotion, Nonprescription Pathways, and Advanced Manufacturing: FDA’s Key Focus Areas in 2024 and What’s Next for 2025
2025-01-23
LATEST
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
Lilly’s Omvoh’s Two-Year Journey Confirms Lasting Impact on Crohn’s Disease Treatment
2025-02-08
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top